Approved predictive biomarkers, such as tumor PD-L1 expression, microsatellite instability (MSI), and the last tumor mutation burden (TMB), have been associated with higher response rates accompanied by extended overall survival (OS) across several cancer types [12,13,14,15]. This evidence concerns the gene CD274 and neoplasm.